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Abstract
Objective
Several papers have reported elevated plasma levels of natriuretic peptides in patients with
a previous diagnosis of cancer. We have explored whether N-terminal pro-brain natriuretic
peptide (NT-proBNP) plasma levels predict a future diagnosis of cancer in patients with cor-
onary artery disease (CAD).
Methods
We studied 699 patients with CAD free of cancer. At baseline, NT-proBNP, galectin-3,
monocyte chemoattractant protein-1, soluble tumor necrosis factor-like weak inducer of ap-
optosis, high-sensitivity C-reactive protein, and high-sensitivity cardiac troponin I plasma
levels were assessed. The primary outcome was new cancer diagnosis. The secondary out-
come was cancer diagnosis, heart failure requiring hospitalization, or death.
Results
After 2.15±0.98 years of follow-up, 24 patients developed cancer. They were older (68.5
[61.5, 75.8] vs 60.0 [52.0, 72.0] years; p=0.011), had higher NT-proBNP (302.0 [134.8,
919.8] vs 165.5 [87.4, 407.5] pg/ml; p=0.040) and high-sensitivity C-reactive protein (3.27
[1.33, 5.94] vs 1.92 [0.83, 4.00] mg/L; p=0.030), and lower triglyceride (92.5 [70.5, 132.8] vs
112.0 [82.0, 157.0] mg/dl; p=0.044) plasma levels than those without cancer. NT-proBNP
(Hazard Ratio [HR]=1.030; 95% Confidence Interval [CI]=1.008-1.053; p=0.007) and
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triglyceride levels (HR=0.987; 95%CI=0.975-0.998; p=0.024) were independent predic-
tors of a new cancer diagnosis (multivariate Cox regression analysis). When patients in
whom the suspicion of cancer appeared in the first one-hundred days after blood extrac-
tion were excluded, NT-proBNP was the only predictor of cancer (HR=1.061; 95%
CI=1.034-1.088; p<0.001). NT-proBNP was an independent predictor of cancer, heart fail-
ure, or death (HR=1.038; 95%CI=1.023-1.052; p<0.001) along with age, and use of insulin
and acenocumarol.
Conclusions
NT-proBNP is an independent predictor of malignancies in patients with CAD. New studies
in large populations are needed to confirm these findings.
Background
Patients with coronary artery disease (CAD) are not only at risk of developing cardiovascular
events, but may also develop malignancies. Cancer shares some risk factors with CAD, as age,
smoking, and even some dietary patterns could lead to the development of both disorders [1–
3]. Therefore, finding biomarkers that predict risk of cancer in addition to that of cardiovascu-
lar events could be useful in CAD patients.
Natriuretic peptides are secreted by cancer cells [4,5] and N-terminal fragment of pro-brain
natriuretic peptide (NT-proBNP) levels are increased in patients with cancer [6]. However, it
has not been demonstrated whether NT-proBNP may predict the appearance of malignancies.
In order to study if increased NT-proBNP plasma levels predict cancer, we studied 704 pa-
tients with CAD who were free of malignancies at baseline. We also tested these biomarkers:
monocyte chemoattractant protein-1 (MCP-1) and soluble tumor necrosis factor-like weak in-
ducer of apoptosis (sTWEAK), both involved in inflammation and atherothrombosis, among
other processes [7–9]; galectin-3, related to malignancies, heart failure, thrombosis, and renal
dysfunction [10,11]; and high-sensitivity cardiac troponin I, which has been described to have
prognostic value in stable CAD [12]. High-sensitivity C-reactive protein was studied as a refer-
ence given the large amount of information published on this biomarker.
Methods
Patients
The BACS & BAMI (Biomarkers in Acute Coronary Syndrome & Biomarkers in Acute Myo-
cardial Infarction) studies included patients admitted to the Madrid-area hospitals Fundación
Jiménez Díaz, Fuenlabrada, Móstoles, and Alcorcón with either non-ST elevation acute coro-
nary syndrome or ST-elevation myocardial infarction. Inclusion criteria have been detailed
previously [13]. Exclusion criteria were: age over 85 years, coexistence of other significant car-
diac disorders except left ventricular hypertrophy secondary to hypertension, coexistence of
any condition that could limit patient survival, impossibility to perform revascularization
when indicated, patients who were not clinically stable at day six of admission, and subjects in
whom follow-up was not possible.
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Ethics Statement
The research protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinky as
reflected in a priori approval by the human research committees of the institutions participat-
ing in this study: Fundación Jiménez Díaz, Hospital Fundación Alcorcón, Hospital de Fuenla-
brada y Hospital Universitario de Móstoles. All patients signed informed consent documents.
Study Design
In addition to plasma withdrawal at discharge, in the BACS & BAMI studies a second plasma
sample was extracted 6–12 months later, on an outpatient basis. This paper is a sub-study of
the BACS & BAMI studies, and reports the clinical and analytical findings obtained at this sec-
ond plasma extraction, relating them to subsequent follow-up. Then, the moment of this sec-
ond plasma extraction is considered to be the baseline visit of this sub-study. At this point, all
patients were free of a diagnosis of cancer and even of any symptoms or signs suggestive of
this diagnosis.
Between July 2006 and April 2010, 1,898 patients were discharged from the participant hos-
pitals with a diagnosis of non-ST elevation acute coronary syndrome or ST-elevation acute
myocardial infarction. Of these, 704 were eligible for this sub-study (Fig 1). The baseline visit
and blood extraction for this sub-study took place between January 2007 and February 2011.
The last follow-up visits took place in May 2012.
The primary outcome was the development of a new cancer with histological confirmation,
excluding non-melanocytic skin tumors. The secondary outcome was the combination of new
cancer, death, or heart failure requiring hospital admission.
At baseline, clinical variables were recorded and 12-hour fasting venous blood samples were
withdrawn and collected in Ethylene-Diamine-Tetra-Acetic Acid. Blood samples were centri-
fuged at 2,500 g for 10 minutes and plasma was stored at -80°C. Patients were seen every year
Fig 1. Recruitment flow-chart. CAD: Coronary artery disease.NSTEACS:Non-ST elevation Acute
Coronary Syndrome. STEMI: ST-elevation myocardial infarction.
doi:10.1371/journal.pone.0126741.g001
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at their hospital. At the end of follow-up (maximum 4.6 years) the medical records were re-
viewed and patient status was confirmed by telephone contact.
Analytical Studies
The investigators who performed the laboratory determinations (OL, LBC, JMV, and DA)
were unaware of the clinical data. Plasma concentrations of MCP-1, galectin-3, and sTWEAK
were determined in duplicate using commercially available enzyme-linked immunosorbent
assay kits (BMS279/2 Bender MedSystems; DCP00, R&D Systems; BMS2006INST, Bender
MedSystems; respectively) following the manufacters’ instructions. Intra- and inter-assay coef-
ficients of variation were 4.6% and 5.9% for MCP-1, 6.2% and 8.3% for galectin-3, and 6.1%
and 8.1% for sTWEAK, respectively. High-sensitivity C-reactive protein was assessed by latex-
enhanced immunoturbidimetry (ADVIA 2400 Chemistry System, Siemens, Germany), NT-
pro-BNP by immunoassay (VITROS, Orthoclinical Diagnostics, U.S.A.), and high-sensitivity
cardiac troponin I was assessed by direct quimioluminiscence (ADVIA Centaur, Siemens, Ger-
many). Lipids, glucose, and creatinin were determined by standard methods (ADVIA 2400
Chemistry System, Siemens, Germany).
Statistical Analysis
Quantitative data did not follow a normal distribution and are displayed as median (interquar-
tile range) and compared using the Mann-Whitney test for two independent samples and by
the Kruskal-Wallis test for three or more samples. Qualitative variables are displayed as per-
centages and compared by χ2 or Fisher exact test when appropriate. Univariate Cox regression
analysis was used to study the predictive power of the biomarkers studied along with these vari-
ables: age, sex, body-mass index, diabetes, smoking, hypertension, systolic blood pressure, pre-
vious heart failure, peripheral artery disease, cerebrovascular events, atrial fibrillation, ejection
fraction<40%, LDL (low-density lipoprotein) cholesterol, HDL (high-density lipoprotein)
cholesterol, triglycerides, non-HDL cholesterol, glycemia, glomerular filtration rate (Chronic
Kidney Disease Epidemiology Collaboration method); therapy with aspirin, clopidogrel, aceno-
cumarol, statins, oral antidiabetic drugs, insulin, angiotensin-converting enzyme inhibitors, an-
giotensin receptor blockers, aldosterone receptor blockers, betablockers, and diuretics; type of
last acute coronary event, number of diseased vessels, use of percutaneous revascularization,
drug-eluting stents, coronary artery by-pass graft, and existence of complete revascularization
at that event.
Multivariate Cox regression analysis was performed with forward, stepwise selection, in-
cluding the biomarkers studied and all the variables mentioned above, in order to assess which
variables were independently associated with the primary and the secondary outcomes. Vari-
ables with p<0.05 were entered into the model, and those with p>0.10 were removed. Univari-
ate and multivariate linear regression analyses were performed to assess the relationship of
NT-proBNP plasma levels with age, glomerular filtration rate, triglycerides and the other bio-
markers studied. Analyses were performed with SPSS 19.0 (SPSS Inc., New York).
Results
NT-proBNP and cancer
Five patients were lost to follow-up, leaving 699 patients for analysis. Age was 60.0 (52.0, 72.0)
years, and there were 75.3% men in the population studied. After 2.15±0.98 years of follow-up,
24 patients developed a new cancer. They were located in lungs (4), prostate (4), larynx (3), uri-
nary bladder (3), colon (2), esophagus (2), breast (2), kidneys (1), and pancreas (1). There was
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also 1 liposarcoma and 1 amigdalar lymphoma. A histological analysis revealed 12 carcinomas,
9 adenocarcinomas, 1 lymphoma, 1 liposarcoma, and 1 urotelial cancer. Only one lung cancer
was a small-cell carcinoma. Patients developing malignancies were older (68.5 [61.5, 75.8] vs
60.0 [52.0, 72.0] years; p = 0.011) and had higher NT-proBNP (302.0 [134.8, 919.8] vs 165.5
[87.4, 407.5] pg/ml; p = 0.040), and high-sensitivity C-reactive protein (3.27 [1.33, 5.94] vs 1.92
[0.83, 4.00] mg/L; p = 0.030), and lower triglyceride (92.5 [70.5, 132.8] vs [112.0 (82.0, 157.0]
mg/dl; p = 0.044) plasma levels than those remaining stable, without differences in the other
variables studied (Table 1 and Fig 2), including previous or present smoking. The percentage of
present smokers at baseline was very low (6.6%).
NT-proBNP levels were 301.0 pg/ml in the case of lymphoma, 357.5 (138.8, 803.5) pg/ml in
cases of lung cancer, 705.5 (178.0, 1082.0) pg/ml in prostatic cancer, and 291.0 (85.4, 931.0) pg/
ml in all the other patients with malignancies, showing no differences among them (p = 0.720
for the comparison between the last 3 groups). NT-proBNP levels were 301.0 (103.8, 919.8)
and 303.0 (115.8, 876.5) pg/ml in patients developing carcinoma and adenocarcinoma, respec-
tively (p = 0.808).
A univariate Cox regression analysis revealed that only age (hazard ratio [HR] = 1.036 [95%
confidence interval (CI) = 1.002–1.072]; p = 0.039), and NT-proBNP (HR = 1.016 [CI = 1.001–
1.033] per 100 pg/ml increment; p = 0.041) and triglyceride (HR = 0.988 [CI = 0.978–0.999];
p = 0.032) plasma levels were associated with a new diagnosis of cancer. All other variables dis-
played in Table 1 did not reach statistical significance (not shown).
By multivariate Cox regression analysis, only NT-proBNP (HR = 1.030 [CI = 1.008–1.053]
per 100 pg/ml increase; p = 0.007) and triglyceride levels (HR = 0.987 [CI = 0.975–0.998];
p = 0.024) remained as independent predictors of a new diagnosis of cancer. There was no dif-
ference in the use of statins between both groups (Table 1). No patients in the cancer group
were receiving fibrates, as compared to 6.1% in the group that had not developed cancer
(p = 0.390).
In four patients, the suspicion of cancer was raised during the first one hundred days of fol-
low-up. These patients showed no significant differences in age, glomerular filtration rate, or
NT-proBNP (121.3 [51.8, 700.3] vs 317.0 [175.3, 981.3] pg/ml; p = 0.157), triglyceride (81.5
[61.5, 95.5] vs 92.5 [72.5, 136.7] mg/dl; p = 0.273), glucose, LDL, HDL, non-HDL, high-sensi-
tivity C-reactive protein, MCP-1, galectin-3, high-sensitivity cardiac troponin I, and sTWEAK
plasma levels as compared to those presenting later. When Cox multivariate regression analysis
was repeated excluding these four patients, NT-proBNP (HR = 1.061 [CI = 1.034–1.088] per
100 pg/ml increase; p<0.001) was the only variable showing independent predictive value for
the appearance of new malignancies.
Relationship of NT-proBNP with other variables
NT-proBNP levels were higher in women than in men (239.0 [130.5, 561.5] vs 156.0 [82.6,
359.0] pg/ml; p<0.001), and in patients with hypertension (225.0 [114.0, 530.0] vs 111.5 [62.7,
223.0] pg/ml; p<0.001) and with previous atrial fibrillation (886.0 [316.0, 1860.0] vs 162.0
[85.9, 378.0] pg/ml; p<0.001) as compared with those not suffering these conditions. Linear re-
gression analyses were performed to assess the extent to which NT-proBNP levels could be ex-
plained by other variables. Given that the distribution of all biomarkers was asymmetric, we
used logarithms for this analysis. NT-proBNP showed significant but mild correlations with
age, glomerular filtration rate, and with plasma levels of high-sensitivity C-reactive protein,
high-sensitivity cardiac troponin I, MCP-1, galectin-3, and triglycerides, (Fig 3), indicating that
these variables did not explain most of NT-proBNP variability. The correlation with body-
mass index and sTWEAK was not significant (R2 = 0.002, p = 0.305; and R2 = 0.000, p = 0.856,
N-Terminal Pro-Brain Natriuretic Peptide Is Associated with Cancer
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Table 1. Characteristics of patients with and without cancer.
Characteristic Patients with cancer (N = 24) Patients without cancer (N = 675) P Value
Age (yr) 68.5 (61.5, 75.8) 60.0 (52.0, 72.0) 0.011
Male sex (%) 70.8 75.4 0.632
Body-mass index (Kg/m2) 27.4 (23.8, 30.9) 28.4 (25.8, 30.9) 0.212
Diabetes (%) 20.8 24.9 0.812
Smoker (%) 83.3 73.5 0.551
Hypertension (%) 75.0 65.0 0.386
Systolic Blood Pressure (mm Hg) 128.0 (112.5, 140.0) 130.0 (120.0, 140.0) 0.397
Previous heart failure (%) 4.2 7.4 1.000
Peripheral artery disease (%) 4.2 3.9 0.618
Cerebrovascular events (%) 0.0 3.6 1.000
Ejection fraction < 40% (%) 20.8 11.6 0.190
Present or past atrial ﬁbrillation 8.3 4.9 0.341
MEDICAL THERAPY
Acetylsalicylic acid (%) 95.8 91.9 0.713
Clopidogrel (%) 66.7 67.9 1.000
Acenocumarol (%) 4.2 6.1 1.000
Statins (%) 83.3 87.7 0.525
Oral antidiabetic drugs (%) 16.7 17.9 1.000
Insulin (%) 0.0 6.7 0.393
Angiotensin-converting enzyme inhibitors (%) 58.3 55.0 0.836
Angiotensin receptor blockers (%) 16.7 16.4 1.000
Aldosterone receptor blockers (%) 4.2 5.8 1.000
Betablockers (%) 70.8 76.3 0.626
Diuretics (%) 25.0 19.3 0.440
DATA AT LAST ACUTE CORONARY EVENT
STEMI/Non-STEACS (%) 50.0/50.0 38.4/61.6 0.288
Number of vessels diseased 1.0 (1.0, 2.0) 1.0 (1.0, 2.0) 0.911
Percutaneous interventionism (%) 83.3 73.2 0.350
Drug-eluting stent (%) 33.3 47.6 0.213
Coronary artery bypass graft (%) 0.0 5.9 0.390
Complete revascularization (%) 58.3 65.3 0.535
ANALYTICAL DATA
LDL cholesterol (mg/dl) 78.5 (62.3, 95.0) 81.0 (66.0, 96.0) 0.495
HDL cholesterol (mg/dl) 44.0 (37.0, 50.8) 42.0 (36.0, 49.0) 0.530
Non-HDL cholesterol 95.5 (82.0, 115.0) 106.0 (90.0, 123.0) 0.141
Triglycerides (mg/dl) 92.5 (70.5, 132.8) 112.0 (82.0, 157.0) 0.044
Glycemia (mg/dl) 96.5 (92.3, 107.8) 100.0 (90.0, 115.0) 0.352
GFR (CKD-EPI) (ml/min/1.73 m2) 69.8 (58.5, 88.2) 78.1 (63.6, 90.0) 0.160
High-sensitivity C-reactive protein (mg/l) 3.27 (1.33, 5.94) 1.92 (0.83, 4.00) 0.030
NT-ProBNP (pg/ml) 302.0 (134.8, 919.8) 165.5 (87.4, 407.5) 0.040
MCP-1 (pg/ml) 154.4 (125.1, 167.6) 129.6 (104.2, 165.6) 0.167
Galectin-3 (ng/ml) 8.07 (5.59, 10.00) 7.78 (6.02, 9.72) 0.795
High-sensitivity troponin I (ng/ml) 0.005 (0.000, 0.018) 0.003 (0.000, 0.010) 0.318
sTWEAK (pg/ml) 169.9 (149.0, 237.4) 201.9 (151.9, 265.4) 0.354
CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; GFR: glomerular ﬁltration rate; HDL: high-density lipoprotein; LDL: low-density lipoprotein
MCP-1: monocyte chemoattractant protein-1; Non-STEACS: Non-ST elevation acute coronary syndrome; NT-Pro-BNP: Pro-Brain natriuretic peptide;
STEMI: ST-elevation myocardial infarction; sTWEAK: soluble tumor necrosis factor-like weak inducer of apoptosis. Quantitative variables are displayed
as median (interquartile range), as they did not follow a normal distribution.
doi:10.1371/journal.pone.0126741.t001
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respectively). By multivariate linear regression analysis all the variables exhibiting a significant
relationship with NT-proBNP at univariate analysis were significant, with the exception of
galectin-3 (Table 2). These variables explained about 41% of the variations of NT-proBNP.
NT-proBNP in the prediction of cancer, heart failure and death
In addition to 24 cancers, 19 patients developed heart failure, and 23 died, yielding a total of 66
events. However, some patients had two events: 9 presented heart failure and death and 6 had
developed a new malignancy and death. So the total number of patients having at least one
event was 51.
The cause of death was heart failure in 5 cases, cancer in 4, unknown in 5, and sudden death
in 3. Pancreatitis, infection, renal failure, digestive bleeding, bowel ischemia, and cholecystitis
accounted for 1 death each.
At multivariate Cox regression analysis, NT-proBNP was an independent predictor of the
outcome of new cancer diagnosis, heart failure or death, along with age and use of acenocu-
marol and insulin (Table 3).
Discussion
Patients with CAD have increased probabilities of developing malignancies. This is so because
the incidence of cancer increases with age [1], tobacco consumption and some dietary patterns
that promote CAD [2,3]. Thus, predicting the risk of cancer in patients with CAD could be
of interest.
Fig 2. Box graphs showing data of the different analytical variables in patients with and without
cancer. Boxes represent the interquartile ranges, with a thick line inside representing the median value.
Points outside boxes represent individual values that are not included in the interquartile range.CKD-EPI:
Chronic Kidney Disease-Epidemiology Collaboration Method;GFR:Glomerular Filtration Rate; HDL:High-
density lipoprotein; LDL: Low-density lipoprotein.NT-proBNP: N-terminal pro-brain natriuretic peptide;
sTWEAK: soluble tumor necrosis factor-like weak inducer of apoptosis.
doi:10.1371/journal.pone.0126741.g002
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NT-proBNP is derived from pre-proBNP secreted by the ventricular myocardium [14] and
is used mainly for the diagnosis of heart failure [15]. In addition, it may predict the develop-
ment of heart failure and death in patients with cardiovascular disease [13,14]. However, NT-
proBNP could have predictive power beyond cardiovascular risk. In fact, this biomarker is as-
sociated with total death in patients with cardiovascular diseases [14] and in elderly subjects
[16–19].
We describe for the first time that NT-proBNP is also an independent predictor of the ap-
pearance of malignancies in patients with CAD. Until now, natriuretic peptides have been in-
vestigated as predictors of cardiac toxicity secondary to chemotherapy [20]. More recently, a
possible relationship between natriuretic peptide plasma levels and cancer itself has been sug-
gested. In fact, patients with cancer may have elevated BNP levels in the absence of volume
overload [6,21]. In patients over 40 years of age with previous elective non-cardiac surgery,
NT-proBNP levels equal to or higher than 125 pg/ml were independently associated with a
Fig 3. Linear regressions showing the correlations of NT-proBNPwith age and other biomarkers
studied.Correlations were significant but mild with age, Glomerular Filtration Rate (GFR) as assessed by the
Chronic Kidney Disease Epidemiology Collaboration Method (CKD-EPI), high-sensitivity C-reactive protein
(hs-CRP), high-sensitivity cardiac troponin I (hs-cTnI),monocyte chemoattractant protein-1 (MCP-1),
galectin-3 (Gal3), and triglyceride plasma levels. Log: Logarithm.
doi:10.1371/journal.pone.0126741.g003
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diagnosis of lung cancer after excluding patients with heart failure, CAD, and other conditions
known to affect this biomarker [22]. Although natriuretic peptides had been shown to be se-
creted by small-cell lung cancer [4,5], only 15% of the cases reported in this study, and one in
the present paper, had this type of cancer, suggesting that other tumors could also produce
NT-proBNP. In addition, NT-proBNP was an independent predictor of survival in patients
with non-Hodgkin lymphoma treated with chemotherapy, after excluding those who were can-
didates for palliative chemotherapy and those with human immunodeficiency virus infection
[23]. Twelve percent had previous heart disease and the median ejection fraction was 65%. Of
interest, NT-proBNP levels were associated with the involvement of two or more extranodal
sites, suggesting a potential relationship with the stage of this malignancy. Similarly, increased
NT-proBNP plasma levels predict the progression of metastatic renal carcinoma [24]. Al-
though hematological and lung cancer seem to have been especially related to NT-proBNP lev-
els, in our series there were no differences in plasma levels of this biomarker among these
groups of patients with cancer, and the groups of patients with all other tumors. Nevertheless,
in our series there was only one case of lymphoma. Also, we found no differences among the
various histopathological types of cancer, although the small number of patients analyzed in
each subgroup limits the validity of this observation.
At present, it is well known that natriuretic peptides may be produced by cancer cells. In
this regard, small-cell lung cancer may secrete both pro-atrial natriuretic peptide and BNP
[4,5]. Also, BNP is expressed both in normal adrenal glands and in adrenal tumors [25], sug-
gesting that natriuretic peptides may have other roles unrelated to the cardiovascular system.
Table 2. Multivariate linear regression analysis showing the influence of other variables on N-terminal
probrain natriuretic peptide levels.
Coefﬁcient 95% CI P value
Intercept 5.730 3.839, 7.621 <0.001
Age 0.022 0.013, 0.031 <0.001
Log hs-CRP 0.139 0.060, 0.218 <0.001
Log hs-cTnl 0.307 0.233, 0.381 <0.001
Log MCP-1 0.358 0.090, 0.626 0.009
Log Gal-3 0.128 -0.098, 0.354 0.266
Log TG -0.264 -0.458, -0.070 0.008
GFR (CKD-EPI) -0.012 -0.018, -0-006 <0.001
R2: 0.407; CI: Conﬁdence Interval; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; Gal-3:
Galectin-3; GFR: glomerular ﬁltration rate; Hs-CRP: high sensitivity C-reactive protein; hs-cTnI: high
sensitivity-core troponin I; Log: Logarithm; MCP-1: monocyte chemoattractant protein-1; TG: Triglycerides.
doi:10.1371/journal.pone.0126741.t002
Table 3. Multivariate Cox regression analysis for the incidence of cancer, heart failure, or death.
Hazard Ratio 95% CI P
Age 1.051 1.020, 1.084 0.001
Acenocumarol 2.415 1.112, 5.243 0.026
Insulin 3.085 1.314, 7.241 0.010
NT-proBNP 1.038* 1.023, 1.052* <0.001
CI: conﬁdence interval. NT-proBNP: N-terminal pro-brain natriuretic peptide.
*Increase in risk per increment of 100 pg/mL plasma concentration.
doi:10.1371/journal.pone.0126741.t003
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ProBNP synthesis may be stimulated by several proinflammatory cytokines, including tumor
necrosis factor-α and some interleukins [26]. Tumor necrosis factor-α and interleukin-6 are
expressed in Reed-Stemberg cells from patients with Hodgkin lymphoma [27,28]. Moreover,
they may predict outcome in diffuse large B-cell lymphomas [29–31] and, as explained, are in-
creased in malignancies at advanced stages [23]. However, the specific cause of the elevation of
natriuretic peptide plasma levels seen in cancer has not been elucidated. In recent years, it has
been demonstrated that natriuretic peptides, or compounds with similar activity, decrease the
number of several cancer cells in vitro through a reduction of DNA synthesis [32] and inhibi-
tion of c-Fos and c-Jun protooncogenes [33], inhibit lung metastases and skin carcinogenesis
in animal models [34,35], and diminish the expression of vascular endothelial growth factor
and that of its receptor VEGFR2, thus having the potential to control vasculogenesis [36]. One
work has shown opposite effects of natriuretic peptides on carcinogenesis depending on their
concentrations [37]. In that paper, atrial natriuretic peptide enhanced proliferation of human
gastric cells in vitro at low concentrations, but inhibited their proliferation through cyclic gua-
nosine 3’5’ monophosphate-dependent or -independent pathways when it was present at high
concentrations [37]. Then, given that most data suggest an anti-cancer effect of natriuretic pep-
tides, the possibility exists that their production by cancer cells represents a negative feed-back
mechanism to control tumor growth. In this case, the NT-proBNP elevation shown here would
only be a response to the existence of malignancies. Nevertheless, the fact that natriuretic pep-
tides are related with mechanisms of cancer which are common to multiple malignancies
would be in agreement with our findings, since we did not observe significant differences in
NT-proBNP levels among patients with different types of cancer.
In our population, low triglyceride levels were also independently associated with the devel-
opment of malignancies in the absence of significant differences in lipid-lowering therapy. Al-
though there is no evidence of a causal relationship [38], low cholesterol levels are associated
with cancer even at preclinical stages [39]. This fact could raise the suspicion that some cancers
were present at the moment of blood extraction. This is possible, given that there is a lapse of
time between the moment when cancer develops and the first signs or symptoms of the disease
appear. We therefore hypothesize that increased NT-proBNP levels could indicate the exis-
tence of a tumor that is not made evident using the tools available in current clinical practice.
In that case, NT-proBNP could be useful for early detection of malignancies. Nevertheless, all
patients showing signs or symptoms of cancer at baseline were excluded even if the diagnosis
was confirmed later. Moreover, we performed a second multivariate analysis excluding patients
in whom the first symptoms or signs of cancer presented during the first one hundred days of
follow-up. In this way we tried to separate the cases of patients that could theoretically have no-
ticed some abnormalities in the weeks before blood extraction for the study though did not re-
port them to their doctors, perhaps because the patients considered them unimportant. In this
analysis, NT-proBNP levels were the only independent predictor of future cancer diagnosis,
thereby confirming that this biomarker may predict a future diagnosis of cancer in cases that
are asymptomatic at the moment of blood extraction. Further work is needed to elucidate if it
predicts the development of new cancer or simply detects subclinical tumors.
The possibility of confounding results because NT-proBNP was acting as a marker of heart
failure is highly improbable. First, all patients where stable and had not heart failure when
blood extraction was performed. Second, the presence of previous heart failure was very low
and not different between both groups. Finally, none of the patients who developed cancer in
our series suffered heart failure during follow-up. In addition, the possibility of any other rela-
tionship of NT-proBNP levels with the underlying CAD is also improbable, as in the multivari-
ate analysis we have controlled for a complete set of variables related with this condition.
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Some factors may influence NT-proBNP levels. Increasing age, female sex, hypertension,
atrial fibrillation and decreased glomerular filtration rate are associated with high plasma levels
of this biomarker, while increasing body-mass index may be related to lower NT-proBNP [14,
40, 41]. In this study, NT-proBNP levels were confirmed to be higher in women than in men,
and to increase with age and impaired renal function. However, NT-proBNP remained as an
independent predictor of the development of cancer after controlling for all these variables. Of
interest, increasing age is associated with high NT-proBNP levels and cancer. Although the in-
crease in natriuretic peptide levels could favor the development of cancer, most of the evidence
that we have found in the literature suggests that they seem to have anti-cancer effects [32–37]
and therefore could work as a negative feed-back when malignancies develop.
Finally, NT-proBNP plasma levels were able to predict the development of the composite
outcome integrating cancer, heart failure and death. This is a relevant feature, since patients
are concerned about any event that could shorten their lives or limit their quality of life re-
gardless of whether they are related to any one medical subspecialty or several of them. If
these results are confirmed in future studies, we will be able to enter a new era in the investiga-
tion of biomarkers focusing on the prediction of disorders that can share pathogenic aspects
and have a serious impact on patient lives, even although they are not related to a single medi-
cal specialty.
This work has some limitations. 1) The number of patients diagnosed with cancer during
follow-up was small, and this finding should be confirmed in larger populations. Similarly, it
seems unwise to attempt to establish a cut-off point of NT-proBNP levels for the diagnosis of
future cancer given the limited number of cancer cases reported in this paper. 2) The lack of as-
sociation between tobacco and cancer diagnosis could be surprising. However, given the previ-
ous diagnosis of CAD, most patients had given up smoking, thus reducing the possibility of
finding such a relationship in this population. 3) Finally, plasma withdrawn during the acute
index event has not been studied, because at this point the population was composed of pa-
tients with ST-elevation myocardial infarction and Non-ST-elevation Acute Coronary Syn-
drome. These are clinical entities with differences in the pathophysiology and management.
Given this heterogeneity, mixing plasma findings at this stage could have introduced a bias in
the results.
Conclusions
NT-proBNP is an independent predictor of malignancies in patients with stable CAD. If these
findings are confirmed in further studies, this biomarker could be helpful in assessing the glob-
al prognosis in patients with CAD.
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